8ISM
HSA-Pt compound complex
Summary for 8ISM
| Entry DOI | 10.2210/pdb8ism/pdb |
| Descriptor | Serum albumin, PALMITIC ACID, 7-(2-azanyl-5-chloranyl-phenyl)-3$l^{3}-thia-5,6$l^{4}-diaza-2$l^{3}-platinatricyclo[6.4.0.0^{2,6}]dodeca-1(12),3,6,8,10-pentaen-4-amine (3 entities in total) |
| Functional Keywords | complex, metal binding protein |
| Biological source | Homo sapiens (human) |
| Total number of polymer chains | 1 |
| Total formula weight | 68252.26 |
| Authors | Zhang, J.Z.,Zhang, Z.L. (deposition date: 2023-03-21, release date: 2024-03-27, Last modification date: 2025-08-20) |
| Primary citation | Zhang, Z.,Zhang, J.,Yang, T.,Li, S.,Xu, G.,Liang, H.,Yang, F. Developing an Anticancer Platinum(II) Compound Based on the Uniqueness of Human Serum Albumin. J.Med.Chem., 66:5669-5684, 2023 Cited by PubMed Abstract: To develop the next-generation Pt drug with remarkable activity and low toxicity to maximally inhibit tumor growth, we optimized a Pt(II) thiosemicarbazone compound (C4) with remarkable cytotoxicity to SK-N-MC cells and then constructed a new human serum albumin-C4 (HSA-C4) complex delivery system. The results showed that C4 and the HSA-C4 complex have remarkable therapeutic efficiency and almost no toxicity; they induced apoptosis and inhibited tumor angiogenesis. This system showed potential as a practical Pt drug. This study could pave the way for developing next-generation dual-targeted Pt drugs and achieving their targeting therapy for cancer. PubMed: 37071741DOI: 10.1021/acs.jmedchem.3c00001 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.76 Å) |
Structure validation
Download full validation report
